Quantitative in situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide
Final rept. 1 Apr 2004-30 Apr 2007
YALE UNIV NEW HAVEN CT
Pagination or Media Count:
Somatostatin SST is a peptide hormone implicated in the growth and progression of cancers and SSTR2 is the predominant receptor subtype expressed in breast cancer. We hope to study the pattern of expression and clinical significance of SSTR2 levels in breast cancer. We have developed an algorithm called AQUA that can assess protein expression on tissue microarrays TMA based on molecular co-localization techniques. Our results show that SSTR2 is localized predominantly to the malignant cells although also in vessellymphatic elements. Although expression was not significantly correlated with survival on our TMA, it did appear to be overexpressed compared with benign breast tissue. A vessel compartment has been developed using a multiplexing protocol for co-localization of SSTR2 to tumor and endothelium concurrently. Cell line controls have also been developed as a normalization feature and ELISA assays have been more successful as reference protein measurements. Whole sections of breast cancer are currently being evaluated for SSTR2 expression and preliminary data are presented.
- Medicine and Medical Research